Lumakras® (Sotorasib) Combined with Vectibix® (Panitumumab) Shows Confirmed 30% Objective Response Rate in Patients with Kras g12c-Mutated Metastatic Colorectal Cancer
Phase 1b Results Demonstrate Encouraging Median Progression-Free Survival of 5.7 Months in Difficult-to-Treat Patient Population THOUSAND OAKS, CA — Amgen (NASDAQ: AMGN) today announced updated data from its Phase 1b CodeBreaK 101 study,… Read More



